Table 1.
Study | Time of BMI determination | Cancer | Number and country (% male) |
BMI categories kg/m2 |
Results | Adjusted for | Comment |
---|---|---|---|---|---|---|---|
Reichle et al. (2015) [32] | Pre-diagnosis | Prostate (n = 1958), colorectal (n = 1013), breast (n = 1410), gynecological (n = 572), upper digestive tract (n = 635), urogenital (n = 607), lymphatic (n = 508), others (n = 1970) | n = 8673 Austria (58 %) | <18.5 18.5–24.9 25.0–29.9 ≥30.0 |
1.28 (1.02–1.60) 1.00 (referent) 0.93 (0.87–0.99) 1.06 (0.97–1.15) |
Age at cancer diagnosis, sex, smoking status, primary location, stage | |
Tsang et al. (2016) [15] | Peri-diagnosis (date of receiving radiation therapy) | Distant metastases (bone, brain, others) with primary tumors (lung, breast, others) | n = 4010 Taiwan (55 %) | ≤18.5 18.5–25.0 25.0–29.9 ≥30.0 |
1.41 (1.26–1.58) 1.00 (referent) 0.84 (0.78–0.91) 0.68 (0.57–0.81) |
Age current, sex, performance status, primary tumor site, site of metastasis, multiple, onset of metastasis. EQD, chemotherapy, comorbidities, employment, alcohol, smoking, betel quid chewing, rural town | Alcohol, smoking, age, and comorbidities have a P value greater than 0.05 |
Schlesinger et al. (2014) [11] | Post-diagnosis (average 4 years after diagnosis) | Colorectal | n = 2143 (and n = 7565 in a meta-analysis) Germany (57 %) | 25 ≤ 25.0–29.9 ≥30.0 |
2.12 (1.18–3.80) 1.00 (referent) 0.79 (0.71–0.89) 0.91 (0.80–1.04) |
Age current, sex, alcohol, smoking status, tumor location, family history of CRC, metastases, other cancers (initially) | Prospective cohort study then meta-analysis with 7565 CRC patients |
BMI body mass index, EQD equieffective dose (of radiotherapy), CRC colorectal cancer